Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (5): 498-504.doi: 10.12092/j.issn.1009-2501.2022.05.002

Previous Articles     Next Articles

Role of Nrf2 pathway in flutamide-induced mitochondrial biogenesis

ZHANG Li1, WANG Jin2, LI Huizi2, PENG Hui1, HE Jun1, PENG Shuangqing1, GUO Jiabin1    

  1. 1Chinese PLA Center for Disease Control and Prevention, Beijing 100071, China; 2Chinese PLA Rocket Force Characteristic Medical Center, Beijing 100120, China 
  • Received:2021-12-17 Revised:2022-04-19 Online:2022-05-26 Published:2022-06-06

Abstract:

AIM: To investigate the effect of flutamide on mitochondrial biogenesis and the regulating effect of anoxidative pathway Nrf2 on it.  METHODS: Human hepatocyte HepG2 cells were treated with flutamide (0-50 μmol/L) for 24 h, then mtDNA copy number and protein expression of mitochondrial biogenesis were detected by RT-PCR and WB. The effects of ERK1/2 and the role of Nrf2 pathway in mitochondrial biogenesis were further observed by gene knockdown and protein activation/inhibition methods. RESULTS: Flutamide interfered mitochondrial biogenesis concentration-dependently, the mtDNA copy number, ERK1/2 and PGC-1α proteins increased with the dose. ERK1/2 inhibition and activation regulated flutamide-induced mtDNA copy number and PGC-1α expression, and inhibition of Nrf2 pathway also affected flutamide-induced mtDNA copy number and expression of PGC-1α, as well as ERK1/2 expression. CONCLUSION: Flutamide affects mitochondrial biogenesis, and the antioxidant pathway Nrf2 may be involved in the regulation of flutamine-induced mitochondrial biogenesis by regulating ERK1/2.

Key words: mitochondrial biogenesis, flutamide, Nrf2, ERK1/2, PGC-1α

CLC Number: